Exicure, Inc.

141 articles with Exicure, Inc.

• Exicure Announces Pricing of $27.5 Million Public Offering of Common Stock

  12/19/2019

  The offering is expected to close on or about December 23, 2019 subject to customary closing conditions.

• Exicure Announces Proposed Public Offering of Common Stock

  12/18/2019

  Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering

•  Exicure Announces First Neurological Development Program in Friedreich’s Ataxia and Expands Scientific Advisory Board

  12/16/2019

  Exicure, Inc. (NASDAQ:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced Friedreich’s ataxia (FA) as the therapeutic indication for the company’s first neurology development program.

• Exicure Reports Activity of AST-008 in Patients with Merkel Cell Carcinoma and Will Enroll Patients in Phase 2 Study

  12/11/2019

  Exicure, Inc. (NASDAQ:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced an update from its Phase 1b/2 trial with AST-008 in patients with solid tumors.

• Exicure and Allergan Enter Into Collaboration, Option and License Agreement to Discover and Develop SNA-based Treatments for Hair Loss Disorders

  11/14/2019

  Exicure to Receive $25 Million Upfront Payment and Up to $725 Million in potential Milestones

• Exicure Reports Third Quarter 2019 Financial Results and Recent Developments

  11/7/2019

  Exicure, Inc., a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid technology, reported financial results for the third quarter ended September 30, 2019 and provided an update on corporate progress.

• Exicure to Present at 2019 BIO Investor Forum

  10/21/2019

  The webcast will be archived for approximately 30 days following the event.

• Exicure Presents Positive Biomarker Results from Clinical Trial of XCUR17

  10/16/2019

  XCUR17 clinical results announced in presentation at the 15th Annual Meeting of the Oligonucleotide Therapeutics Society in Munich

• Exicure to Present Clinical Results from XCUR17 at the 15th Annual Meeting of the Oligonucleotide Therapeutics Society

  10/14/2019

  Exicure, Inc., a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced that its CEO, David Giljohann, PhD, will present clinical data from the company’s Phase 1 study of its drug candidate XCUR17 in psoriasis.

• Exicure to Present at 2019 International Oligonucleotide and Peptide Conference

  9/17/2019

  Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that its chief operating officer, Dr. Matthias Schroff, will give a company presentation titled, “Multitargeting Spherical Nucleic Acids: Advantages & Applications,” on Wednesday, September 18, 2019 at 11:40 am GMT at the 2019 International Oligonucleotide and Peptide Conference

• Exicure to Present at Upcoming Investor Conferences

  9/3/2019

  Exicure, Inc. announced presentations at the following investor conferences during the months of September and early October

• 

  BioSpace Movers and Shakers, Aug. 9

  8/9/2019

  Biopharma companies strengthen their senior leadership teams and boards of directors.

• Exicure Reports Second Quarter 2019 Financial Results and Recent Developments

  8/8/2019

  Exicure, Inc., a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, reported financial results for the second quarter ended June 30, 2019 and provided an update on corporate progress.

• Exicure Appoints Dr. Bali Muralidhar of Abingworth LLP and Bosun Hau of Tybourne Capital Management to its Board of Directors

  8/7/2019

  Dr. Bali Muralidhar, a partner at Abingworth LLP, and Mr. Bosun Hau, a managing director and co-head of private equity at Tybourne Capital Management, to its Board of Directors.

• Exicure Announces the Closing of its Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

  8/2/2019

  Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced the closing of its previously announced underwritten public offering of 31,625,000 shares of its common stock to the public at $2.00 per share, which included the exercise in full by the underwriters of their option to purchase 4,125,000 additional shares of common stock.

• Exicure Announces Uplisting to Nasdaq Capital Market and Pricing of $55 Million Public Offering of Common Stock

  7/31/2019

  Stock will begin trading on the Nasdaq Capital Market under the symbol “XCUR” at the opening of trading on July 31, 2019, following its previously announced approval to list its common stock on the Nasdaq Capital Market.

• Exicure Announces Proposed Public Offering of Common Stock and Uplisting to Nasdaq Capital Market

  7/30/2019

  Exicure, Inc. (OTCQB: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering

• Exicure Appoints Jeffrey L. Cleland and Tim Walbert to Board of Directors

  7/22/2019

  Exicure, Inc., a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced its appointment of Jeffrey L. Cleland, Ph.D. and Timothy P. Walbert to its Board of Directors.

• Exicure Co-Founder Chad Mirkin Wins Kabiller Prize in Nanoscience and Nanomedicine

  7/11/2019

  Exicure, Inc., a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, is proud to announce Co-founder Chad A. Mirkin has been awarded the $250,000 Kabiller Prize in Nanoscience and Nanomedicine for discovering and developing spherical nucleic acids (SNAs).

• Exicure Announces Preclinical Data Supporting Development of SNA Technology in the Central Nervous System Conference call scheduled for 8:00 am ET on June 27, 2019

  6/26/2019

  Exicure, Inc., a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced data from a preclinical study evaluating the biodistribution of SNAs in the non-human primate central nervous system.